Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Endlicher

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Surgical Endoscopy|December 21, 2006
Self-expanding Polyflex plastic stents in esophageal disease: various indications, complications, and outcomesC Ott, N Ratiu, E Endlicher, et al.
British Journal of Cancer|November 27, 2001
Protoporphyrin IX distribution following local application of 5-aminolevulinic acid and its esterified derivatives in the tissue layers of the normal rat colonE Endlicher, P Rümmele, F Hausmann, et al.
Deutsche Medizinische Wochenschrift (1946)|May 28, 1998
[Photodynamic diagnosis of gastrointestinal precancerous lesions after sensitization with 5-aminolevulinic acid. A pilot study]H Messmann, R Knüchel, E Endlicher, et al.
Oncology|January 12, 2008
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II studyE Endlicher, M Troppmann, A Kullmann, et al.
Endoscopy|November 11, 2005
Barrett's esophagus: a discrepancy between macroscopic and histological diagnosisE Endlicher, P Rümmele, S Beer, et al.
British Journal of Cancer|March 19, 2009
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II studyF Kullmann, S Hollerbach, M M Dollinger, et al.
Medical Oncology (Northwood, London, England)|November 4, 2017
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trialI Walter, U Schulz, M Vogelhuber, et al.
Oncology|September 7, 2011
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapyF Kullmann, A Hartmann, R Stöhr, et al.
British Journal of Cancer|January 14, 2010
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)F Lordick, B Luber, S Lorenzen, et al.
British Journal of Cancer|March 1, 2012
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerJ Harder, G Ihorst, V Heinemann, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Surgical Endoscopy|December 21, 2006
Self-expanding Polyflex plastic stents in esophageal disease: various indications, complications, and outcomesC Ott, N Ratiu, E Endlicher, et al.
British Journal of Cancer|November 27, 2001
Protoporphyrin IX distribution following local application of 5-aminolevulinic acid and its esterified derivatives in the tissue layers of the normal rat colonE Endlicher, P Rümmele, F Hausmann, et al.
Deutsche Medizinische Wochenschrift (1946)|May 28, 1998
[Photodynamic diagnosis of gastrointestinal precancerous lesions after sensitization with 5-aminolevulinic acid. A pilot study]H Messmann, R Knüchel, E Endlicher, et al.
Oncology|January 12, 2008
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II studyE Endlicher, M Troppmann, A Kullmann, et al.
Endoscopy|November 11, 2005
Barrett's esophagus: a discrepancy between macroscopic and histological diagnosisE Endlicher, P Rümmele, S Beer, et al.
British Journal of Cancer|March 19, 2009
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II studyF Kullmann, S Hollerbach, M M Dollinger, et al.
Medical Oncology (Northwood, London, England)|November 4, 2017
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trialI Walter, U Schulz, M Vogelhuber, et al.
Oncology|September 7, 2011
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapyF Kullmann, A Hartmann, R Stöhr, et al.
British Journal of Cancer|January 14, 2010
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)F Lordick, B Luber, S Lorenzen, et al.
British Journal of Cancer|March 1, 2012
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerJ Harder, G Ihorst, V Heinemann, et al.
Pageof 4